Ewings Sarcoma - A Pipeline Analysis Report

Overview of the drug development pipeline for Ewing's Sarcoma

Ewing's Sarcoma is a rare and malignant, round, blue cell tumor that affects soft tissues and long bones including pelvic bone, femur, ribs, and collar bones. This condition is common in young adults, pediatric patients, and teenagers and it involves long recovery period. The primitive neuroectodermal tumor (PNET) type of Ewing's Sarcoma begin in tissues and progress to the bones. It has been observed that it is the second-most common cancer in adolescents and young adults. Technavio’s market research analysts have predicted that with the introduction of chemotherapy, surgery, and radiation therapy as some of the most promising approaches to treat Ewing's Sarcoma, the global Ewing's Sarcoma market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase I developmental stage. For instance, sponsors such as Bayer developed Regorafenib and Cellectar Biosciences developed CLR 131, which are under phase I development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under preclinical, phase II, and phase I/II stages. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under phase III and discovery developmental stages.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of Ewing's Sarcoma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Bayer
• Celgene
• Eisai

Therapeutic assessment of the drug development pipeline for Ewing's Sarcoma by route of administration

• Intravenous
• Oral
• Subcutaneous
• Intradermal
• Intratumoral

The intravenous route of administration (ROA) involves the administration of liquid substances into a vein. It has been observed that the majority of total therapeutics are being developed for intravenous administration.

Therapeutic assessment of the drug development pipeline for Ewing's Sarcoma by therapeutic modalities

• Small molecule
• Monoclonal antibody
• Vaccine

According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for Ewing's Sarcoma are being developed as small molecules. Small molecules bind with specific biological macromolecules and act as an effector and alter the activity or function of the target.